Literature DB >> 16606392

Antiinflammatory effects of cardiac resynchronization therapy in patients with chronic heart failure.

George N Theodorakis1, Panagiota Flevari, Christos Kroupis, Stamatis Adamopoulos, Efthimios G Livanis, Anna Kostopoulou, Fotis Kolokathis, Ioannis A Paraskevaidis, Dionyssios Leftheriotis, Dimitrios Th Kremastinos.   

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) pacing has been proposed as an additional treatment to medical therapy to improve heart failure patients with left ventricular asynchrony. The aim of this study was to evaluate the influence of CRT treatment on proinflammatory cytokines in patients with heart failure.
METHODS: Twenty patients, with a mean age 64 +/- 2 years, with severe chronic heart failure NYHA class II-IV (mean ejection fraction 25 +/- 2%), were included in the study. Patients were treated with CRT pacing, after failure of optimal therapy. Blood samples were taken at baseline, 3 months after pacing therapy, and after a subsequent 3-month period of no pacing for the assessment of proinflammatory cytokines TNF-alpha and its receptors (sTNFR-I, sTNFR-II), IL-6, adhesion molecules sICAM-1 and sVCAM-1, and the apoptotic indices sFas and sFas-Ligand.
RESULTS: Levels of TNF-alpha, sTNFR-I, and sTNFR-II were reduced at the end of 3 months of CRT therapy and further reduced at the end of the no pacing period (P < 0.05, compared to baseline). Levels of IL-6 also declined after 3 months of CRT pacing (from 8.9 +/- 2.5 pg/mL to 4.7 +/- 1.3 pg/mL, P < 0.05) and this was maintained during the no pacing period (3.9 +/- 1.1 pg/mL P < 0.05 compared to baseline). The adhesion molecule sICAM-1 levels also reduced (from 265 +/- 17 ng/mL to 235 +/- 12, P < 0.05) after 3 months of CRT pacing and remained unchanged at the end of the no pacing period (219 +/- 12 ng/mL, P < 0.05 compared to baseline values).
CONCLUSION: Major proinflammatory cytokines and the adhesion molecule sICAM-1 are reduced with CRT therapy and this effect is maintained for at least 3 months after discontinuation of pacing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606392     DOI: 10.1111/j.1540-8159.2006.00331.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  9 in total

1.  Complement C3a predicts outcome in cardiac resynchronization therapy of heart failure.

Authors:  Gábor Széplaki; András Mihály Boros; Szabolcs Szilágyi; István Osztheimer; Zsigmond Jenei; Annamária Kosztin; Klaudia Vivien Nagy; Júlia Karády; Levente Molnár; Tamás Tahin; Endre Zima; László Gellér; Zoltán Prohászka; Béla Merkely
Journal:  Inflamm Res       Date:  2016-08-04       Impact factor: 4.575

2.  Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy.

Authors:  Abhishek Bose; Quynh A Truong; Jagmeet P Singh
Journal:  J Interv Card Electrophysiol       Date:  2015-02-27       Impact factor: 1.900

Review 3.  Endothelial-Mesenchymal Transition or Functional Tissue Regeneration - Two Outcomes of Heart Remodeling.

Authors:  B Šalingová; Z Červenák; A Adamičková; N Chomanicová; S Valášková; A Gažová; J Kyselovič
Journal:  Physiol Res       Date:  2021-11-30       Impact factor: 1.881

4.  Inflammatory activation following interruption of long-term cardiac resynchronization therapy.

Authors:  Andrzej Rubaj; Piotr Ruciński; Krzysztof Oleszczak; Michał K Trojnar; Maciej Wójcik; Andrzej Wysokiński; Andrzej Kutarski
Journal:  Heart Vessels       Date:  2012-12-16       Impact factor: 2.037

5.  SmartDelay determined AV optimization: a comparison of AV delay methods used in cardiac resynchronization therapy (SMART-AV): rationale and design.

Authors:  Kenneth M Stein; Kenneth A Ellenbogen; Michael R Gold; Bernd Lemke; Ignacio Fernández Lozano; Suneet Mittal; Francis G Spinale; Jennifer E Van Eyk; Alan D Waggoner; Timothy E Meyer
Journal:  Pacing Clin Electrophysiol       Date:  2009-10-10       Impact factor: 1.976

6.  Aggressive cardiac involvement in systemic lupus erythematosus: a case report and a comprehensive literature review.

Authors:  Reza Ashrafi; Pankaj Garg; Ewan McKay; John Gosney; Som Chuah; Gershan Davis
Journal:  Cardiol Res Pract       Date:  2011-02-15       Impact factor: 1.866

7.  The impact of cardiac resynchronization therapy on routine laboratory parameters.

Authors:  András Mihály Boros; Péter Perge; Klaudia Vivien Nagy; Astrid Apor; Zsolt Bagyura; Endre Zima; Levente Molnár; Tamás Tahin; Dávid Becker; László Gellér; Béla Merkely; Gábor Széplaki
Journal:  Interv Med Appl Sci       Date:  2017-03

8.  Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits.

Authors:  Gonçalo Cristóvão; James Milner; Pedro Sousa; Miguel Ventura; João Cristóvão; Luís Elvas; Artur Paiva; Lino Gonçalves; Carlos Fontes Ribeiro; Natália António
Journal:  Stem Cell Res Ther       Date:  2020-05-24       Impact factor: 6.832

9.  Neutrophil-to-lymphocyte ratio predicts response to cardiac resynchronization therapy.

Authors:  Aysen Agacdiken; Umut Celikyurt; Tayfun Sahin; Kurtulus Karauzum; Ahmet Vural; Dilek Ural
Journal:  Med Sci Monit       Date:  2013-05-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.